Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06523803 · ClinicalTrials.gov registry record · Phase 1
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
A Phase 1 study, sponsored by Zymeworks BC.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06523803 is a Phase 1 study that was terminated before completion, run by Zymeworks BC. The registered enrollment target is 32 participants.
The verdict
NCT06523803, a Phase 1 study, was terminated before completion, sponsored by Zymeworks BC.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers.
Interventions
- DRUG ZW171
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06523803
The ClinicalTrials.gov registry entry for NCT06523803 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zymeworks BC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZW171 is the first listed.
NCT06523803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06523803 about?
NCT06523803 is a clinical study titled "A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers". This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers.
What is the current status of trial NCT06523803?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-09-30. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT06523803?
The interventions under investigation include: ZW171 (DRUG).
Who is sponsoring clinical trial NCT06523803?
This trial is sponsored by Zymeworks BC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.